Stelara — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson Stelara — Sales to customers (Note 9) decreased by 5.0% to $3.14B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 41.3%, from $5.35B to $3.14B. Over 2 years (FY 2021 to FY 2024), Stelara — Sales to customers (Note 9) shows an upward trend with a 15.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercialization, while a decrease may signal patent expirations, increased competition, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific flagship pharmaceutical product to ex...
Peer comparison
Comparable to revenue reporting for specific blockbuster drugs or key therapeutic franchises at other large-cap pharmaceutical companies.
jnj_segment_stelara_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.30B | $4.55B | $4.76B | $4.77B | $4.58B | $5.20B | $4.90B | $4.89B | $5.73B | $4.90B | $5.77B | $5.35B | $4.70B | $3.25B | $3.31B | $3.14B |
| QoQ Change | — | +5.9% | +4.6% | +0.4% | -4.1% | +13.6% | -5.8% | -0.2% | +17.2% | -14.4% | +17.7% | -7.2% | -12.2% | -30.8% | +1.7% | -5.0% |
| YoY Change | — | — | — | — | +6.5% | +14.3% | +3.0% | +6.8% | +10.2% | — | +18.0% | -6.5% | — | -33.7% | -42.7% | -41.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's stelara — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported stelara — sales to customers (note 9) of $3.14B in Q3 2025.
- How has Johnson & Johnson's stelara — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's stelara — sales to customers (note 9) decreased by 41.3% year-over-year, from $5.35B to $3.14B.
- What is the long-term trend for Johnson & Johnson's stelara — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's stelara — sales to customers (note 9) has grown at a 15.9% compound annual growth rate (CAGR), from $15.41B to $20.72B.
- What does stelara — sales to customers (note 9) mean?
- The total revenue earned from sales of a specific pharmaceutical product.